Next Article in Journal
Imaging Transcranial Direct Current Stimulation (tDCS) with Positron Emission Tomography (PET)
Next Article in Special Issue
The Long Road of Immunotherapeutics against Multiple Sclerosis
Previous Article in Journal
Cerebellar Transcranial Direct Current Stimulation Improves Maximum Isometric Force Production during Isometric Barbell Squats
Previous Article in Special Issue
Streptococcus thermophilus ST285 Alters Pro-Inflammatory to Anti-Inflammatory Cytokine Secretion against Multiple Sclerosis Peptide in Mice
Open AccessReview

Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know

1
2nd Neurological University Department, Aristotle University of Thessaloniki, AHEPA General Hospital, 54634 Thessaloniki, Greece
2
Public Health Laboratories, Hellenic Pasteur Institute, Athens 11521, Greece
3
Laboratory of Microbiology, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Larissa, Greece
4
Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University, Moscow 117997, Russia
5
Department of Neuroimmunology, Federal Center of Cerebrovascular Pathology and Stroke, Moscow 117342, Russia
6
Department of Molecular Pharmacology and Radiobiology, Pirogov Russian National Research Medical University, Moscow 117997, Russia
*
Authors to whom correspondence should be addressed.
Brain Sci. 2020, 10(4), 234; https://doi.org/10.3390/brainsci10040234
Received: 19 March 2020 / Revised: 6 April 2020 / Accepted: 8 April 2020 / Published: 14 April 2020
(This article belongs to the Special Issue Advances in Multiple Sclerosis Research)
An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study of the gut–brain axis, which mediates the communication between the central nervous system and the gut microbiome. Clinical data arising from many research studies, which have assessed the effects of administered disease-modifying treatments in MS patients to the gut microbiome, are also recapitulated. View Full-Text
Keywords: gut microbiome; gut–brain axis; metagenomics; multiple sclerosis; disease-modifying treatments gut microbiome; gut–brain axis; metagenomics; multiple sclerosis; disease-modifying treatments
Show Figures

Graphical abstract

MDPI and ACS Style

Boziki, M.K.; Kesidou, E.; Theotokis, P.; Mentis, A.-F.A.; Karafoulidou, E.; Melnikov, M.; Sviridova, A.; Rogovski, V.; Boyko, A.; Grigoriadis, N. Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know. Brain Sci. 2020, 10, 234.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop